U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07415811) titled 'Spironolactone and XPB-1 Integrity in the TFIIH Complex' on Jan. 25.
Brief Summary: This is a prospective, interventional, exploratory clinical study designed to evaluate the pharmacokinetics, safety, and biological effects of spironolactone on the degradation of the XPB (ERCC3) protein and its potential impact on the HIV reservoir. Spironolactone is an FDA-approved mineralocorticoid receptor antagonist that has recently been shown in preclinical studies to induce rapid and reversible proteolytic degradation of XPB, a key subunit of the transcription factor IIH (TFIIH) complex, which is essential for cellular transcription, DNA repa...